Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

For healthcare professionals in the UK and Ireland only

The bigger picture of type 2 diabetes:

How to optimise care in the current climate

WEBCAST SERIES

25 & 30 November 2021
7 December 2021

The bigger picture of type 2 diabetes:
How to optimise care in the current climate

This is a uniquely challenging time for everyone working in primary care. Type 2 diabetes is a complex condition, needing careful management; but the recent pandemic has left a great backlog of care. The pressure on healthcare services and the need to safeguard vulnerable patients from potential infection has meant many annual reviews for long-term conditions such as diabetes have been rescheduled or postponed. Now, many of these patients are in urgent need of re-establishing care to reduce their risk of serious complications – but referral times for specialist services are long, and many professionals in primary care feel unsure of how to do what’s best for their patients.

These two webcasts will look at type 2 diabetes and its effects on the cardiovascular, renal and metabolic systems – and how optimising glycaemic control alone is not enough to mitigate the risks of morbidity and mortality for these patients. By providing care that reduces cardiorenal risk as well as managing hyperglycaemia, healthcare professionals in primary care can delay patients’ progression to serious complications needing specialist treatment. The webcasts will look at trial evidence and guidelines available to guide clinical decision-making, as well as offering practical advice on prioritising patients for review and treatment intensification.

What do the webcasts offer?

Live Q&A session with expert speakers ready to answer your questions

On-demand resources – access education at times that work for you

Register for free today and gain access to these events

to access useful resources on type 2 diabetes management

Programme

Introducing CRM: the relationship between cardiovascular, renal and metabolic systems in type 2 diabetes

10 mins

Introduction and welcome

  • Chair’s welcome and important information for attendees
  • The current state of affairs: The impact of the pandemic on diabetes diagnosis and management
  • How could optimising care help to address the referral and review backlog?

30 mins

Introducing CRM: the relationship between cardiovascular, renal and metabolic systems in type 2 diabetes

  • The interconnected relationship between the cardiovascular, renal and metabolic systems
  • Cardiovascular and renal morbidity and mortality in people with type 2 diabetes
  • How clinical guidelines have evolved to reflect the unmet need of addressing cardiovascular and renal morbidity and mortality

20 mins

Live Q&A

  • Live question and answer session where the speakers will answer your questions

Going beyond type 2 diabetes: the multiple cardiovascular, renal and metabolic benefits of Jardiance® (empagliflozin)

10 mins

Introduction: Managing the interplay between organ systems in type 2 diabetes

  • Chair’s welcome and important information for attendees
  • Recap of the interplay between cardiovascular, renal and metabolic systems, and the evidence for their role in diabetes morbidity and mortality
  • How have international guidelines changed to reflect the importance of reducing cardiovascular, renal and metabolic risks?

30 mins

Going beyond type 2 diabetes: the multiple cardiovascular, renal and metabolic benefits of Jardiance® (empagliflozin)

  • Mechanism of action of Jardiance® (empagliflozin) on the cardiovascular, renal and metabolic systems
  • Overview of clinical trial data: What benefits could Jardiance offer in reducing cardiovascular disease, renal disease and heart failure with reduced ejection fraction?
  • Practical considerations – is clinical practice changing in line with the evidence and guidelines?

20 mins

Live Q&A

  • Live question and answer session where the speakers will answer your questions

Speakers

Dr Ameet Bakhai,

Consultant Cardiologist and Research Director, The Royal Free Hospital, London

Dr Sarah Jarvis,

General Practitioner, London and Clinical Director at Patient.info

Dr Yassir Javaid,

GPwSI in Cardiology, Northampton

Dr Frank Joseph,

Consultant Physician in Endocrinology, Diabetes and Internal Medicine, Liverpool

Dr Janaka Karalliedde,

Consultant in Diabetes, Endocrinology and Internal Medicine, London

The Boehringer Ingelheim and Lilly Alliance has provided the funding for this promotional webcast intended for Healthcare Professionals only, including speaker honoraria and presentation development support where applicable. Boehringer Ingelheim and Lilly Alliance products will be discussed in this webcast. Marketing and organisational support has been provided by OmniaMed Communications.
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard (UK) or
https://www.hpra.ie/homepage/about-us/report-an-issue (Ireland). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on
0800 328 1627 (freephone) (UK) or 01 2913960 (Ireland), Fax: +44 1344 742661, or by e-mail: PV_local_UK_Ireland@boehringer-ingelheim.com (Ireland).
PC-GB-105793 | October 2021

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.